Typhoid and Paratyphoid: Enteric Fever Symptoms, Tests and Treatment

Typhoid and paratyphoid are potentially serious systemic Salmonella infections, together called enteric fever. They are different from typical nontyphoidal Salmonella gastroenteritis. Fever and significant illness after a relevant exposure require prompt medical care, even after vaccination. Confidence: high for urgent assessment and culture/resistance investigation; moderate for attributed treatment/prevention pathways, and low for an independently cleared antibiotic ranking or supplement cure.

Table of contents

• Evidence summary: systemic illness, blood cultures and resistance-guided care
• Typhi, Paratyphi and the meaning of enteric fever
• Human carriage, food and water contamination, and delayed illness
• Treatment: antibiotics chosen for the actual illness and susceptibility
• Probiotics, herbal antibiotics and nutrition during recovery
• Prevention: safe food and water plus appropriate typhoid vaccination
• Safety: severe fever, bleeding, worsening pain and possible sepsis
• Azithromycin, live oral vaccination and acute-illness medicine review
• Diagnosis: culture, antibody-test limitations and other febrile illnesses
• Follow-up: fever response, relapse, carriage and work clearance
• Human reservoirs, laboratory susceptibility and evidence limits
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary: systemic illness, blood cultures and resistance-guided care

The CDC clinical original describes blood culture as central to diagnosis and advises against the Widal antibody test because of false positives. Treatment decisions need susceptibility information and a careful travel history.

The CDC treatment overview recommends timely prescribed antibiotics and explains that resistance testing may change the prescription. These are attributed clinical recommendations, not an independently established drug-brand winner.

Identify the organism, the current severity and the intended investigation before interpreting a result or changing treatment. A positive test, a vaccine record and a fever response answer different questions. This review supplies no personal antibiotic dose, numerical cure comparison or population death estimate. Institutional finance is traced separately from authors and underlying trials; public hosting alone does not establish their independence.

Typhi, Paratyphi and the meaning of enteric fever

CDC’s disease overview identifies Salmonella Typhi as the cause of typhoid and Salmonella Paratyphi as the cause of paratyphoid. Both can be life-threatening; similar symptoms do not establish which organism is present.

The 2026-edition CDC Yellow Book distinguishes these bloodstream-associated illnesses from nontyphoidal Salmonella, which commonly causes gastroenteritis. A report saying only “Salmonella” needs further interpretation; do not transfer a stomach-bug management plan to confirmed enteric fever.

Ask what the laboratory identified, which specimen was tested and whether the clinician suspects a systemic infection. A stool result and a blood-culture result have different meanings. Avoid diagnosing typhoid from a rash photograph, a fever pattern or a travel destination alone. The combination of examination, exposure and appropriate investigation is more useful than matching one symptom.

Human carriage, food and water contamination, and delayed illness

The CDC transmission original describes ingestion of bacteria through food or water contaminated by stool, including contamination from a person who feels well but still carries the organism. Symptoms disappearing do not necessarily answer the carriage question.

The CDC clinical overview describes variable incubation and ongoing extensively drug-resistant typhoid associated with Pakistan, including cases without recent international travel. Absence of travel does not rule out disease; an exposure history must be broader than a passport stamp.

Tell the team about where and when you traveled or lived, food and water sources, contacts, illness dates and any antibiotics already taken. A familiar destination, short stay or visiting relatives does not establish immunity. Share relevant details without assigning blame to one household, ethnic group or meal. Prevention and investigation work better when exposure information is accurate.

Treatment: antibiotics chosen for the actual illness and susceptibility

The CDC guidance warns that antimicrobial resistance changes empirical choices, including important Iraq/Pakistan travel distinctions and fluoroquinolone nonsusceptibility in US-diagnosed infection. This is a dated jurisdiction-specific framework, not permission to choose or reuse a drug at home.

Ask whether treatment is empirical while cultures are pending or directed by a known susceptibility result. Clarify when results will be reviewed, whether the route or medicine might change and what to do if vomiting prevents taking it. An initially prescribed drug is not a promise that it will remain appropriate regardless of the laboratory findings.

Take the actual course as prescribed and obtain advice before changing it. Supportive care must fit the person’s intake, illness and other conditions. NHS dehydration guidance supports suitable rehydration and assessment when losses or poor intake cannot be managed safely. No individual fluid amount, hospital-admission threshold or medicine sequence is supplied.

Probiotics, herbal antibiotics and nutrition during recovery

No independently established probiotic, herbal antibiotic, colloidal silver or “typhoid cleanse” is a substitute for clinical care in this review. An effect on bacterial growth in a dish is not proof that a product treats a systemic infection safely. Symptom relief does not demonstrate clearance.

The dated NCCIH probiotic source distinguishes strains and products and describes infection/contamination concerns in vulnerable patients. Its August2019 footer, later warning and unresolved reviewer/study finances remain visible; it is not an enteric-fever efficacy assessment.

Report ongoing poor appetite, weight change or inability to tolerate food. Ask whether nutritional support is needed and what is feasible during recovery. NCCIH supplement precautions support disclosing every ingredient to the team. Bring packaging rather than relying on a product name, including any liquid remedy or supplement taken with an antibiotic. No universal nutrient package or restricted recovery diet is prescribed here.

Prevention: safe food and water plus appropriate typhoid vaccination

The July2026 CDC prevention page emphasizes safe eating/drinking and vaccination when indicated for travel. It states that available typhoid vaccines do not protect against paratyphoid, and vaccination does not eliminate the need for food and water precautions.

Plan safe drinking water and ice, hot thoroughly cooked food, appropriately washed/peeled produce and soap-and-water handwashing. Ask a travel service about current destination advice early enough to review the actual product, previous vaccination and medical history. Do not assume all vaccine ages, boosters or timing are identical across countries.

The March2023 WHO source describes conjugate vaccination in endemic-country childhood programmes. That context differs from a US travel vaccine prescription; its old prequalification count is not presented as current. Make prevention feasible for the actual trip or residence, including water used to brush teeth or prepare food, while keeping vaccination and sanitation as complementary measures.

Safety: severe fever, bleeding, worsening pain and possible sepsis

The August2025 CDC symptoms original describes fever, weakness, headache, abdominal symptoms and possible constipation or diarrhoea. It advises immediate care for fever with significant illness. Do not wait for a rose-spot rash, diarrhoea or a fixed number of fever days.

The July2025 NHS typhoid guidance identifies sudden worsening abdominal pain, black/dark-red stool or bloody/coffee-ground vomit as emergency concerns. If unwell abroad, seek help there rather than waiting to return home. Worsening, persistent or recurrent symptoms after treatment need prompt reassessment.

NHS sepsis guidance treats confusion, difficulty breathing, abnormal pale/blotchy skin, difficulty waking or serious concern about a sick child as reasons for immediate help. Not every sign must be present. Tell the service about travel, suspected enteric fever, prescriptions and any immune treatment; do not explain significant deterioration away as an expected antibiotic effect.

Azithromycin, live oral vaccination and acute-illness medicine review

If azithromycin is actually prescribed, the January2026 NHS interaction original flags anticoagulants, digoxin, immune medicines, antacids and other drugs affecting heart rhythm. Review the exact list with a pharmacist; this is not a recommendation to choose azithromycin in every setting.

The CDC vaccine information statement asks providers to review pregnancy, weakened immunity, allergies and recent antibiotic or antimalarial use. Live oral and injected products have different precautions. A clinician should coordinate medicines and vaccination; do not postpone necessary infection treatment to protect a planned schedule.

NHS kidney-injury guidance supports medication review during fluid loss or reduced urination. Explain existing fluid restrictions and all prescriptions. There is no universal self-stop list or personal restart date here. Oral medicine absorption, vomiting, allergy history and the actual label should be considered with the treatment plan.

Diagnosis: culture, antibody-test limitations and other febrile illnesses

The CDC diagnostic guidance notes that multiple cultures may be needed and that stool/urine are less often positive than blood. A Widal result should not be treated as a confirmed diagnosis or a reliable rule-out. Ask what the requested test can establish.

The CDC laboratory original describes its US public-health submission route through state laboratories/federal agencies; it is not a direct patient mail-in service. Your clinical team should arrange the actual laboratory and any further organism or resistance characterization.

The CDC Yellow Book notes clinical overlap with malaria and the limits of antibody tests distinguishing past infection, vaccination and current illness. Report all relevant travel; a typhoid label should not prevent investigation of another urgent cause of fever. Testing and necessary treatment can proceed together, rather than waiting for every result when the patient is seriously ill.

Follow-up: fever response, relapse, carriage and work clearance

Agree on how fever, alertness, intake and abdominal symptoms will be reviewed. Ask when to contact the team and who receives culture/susceptibility results. Record what you have taken and whether doses were vomited, without altering the course independently. New severe symptoms need care regardless of the planned follow-up date.

The CDC clinical chapter describes relapse, reinfection and chronic carriage as separate possibilities requiring reassessment. Persistent fever can prompt investigation for an ongoing focus or another treatment need. No fever-duration statement is a personal safe waiting guarantee.

The CDC treatment source advises avoiding food preparation until cleared and notes that healthcare, childcare and food-handling workers may need doctor-led clearance. Ask local health-protection services about required samples, contacts, school and return to work; a generic diarrhoea symptom-free rule is not universal enteric-fever clearance. Clinical recovery and protection of others both matter.

Human reservoirs, laboratory susceptibility and evidence limits

The WHO disease original identifies humans as the host for Typhi and describes spread into the bloodstream. This should not be confused with the animal-associated exposure patterns of many other Salmonella infections. A finding in a different organism or laboratory system cannot simply be transferred to enteric fever.

A susceptibility result informs the clinician’s prescription; it does not prove a supplement cure or specify every practical treatment detail. The team must consider the person, disease site, severity, safety and response. This review does not convert laboratory inhibition of bacteria into a human clinical benefit claim.

Future antibiotic or vaccine comparisons should define population, exposure, comparator, clinically meaningful outcomes and complete funder/author interests. A conjugate-vaccine recommendation, a travel prevention statement and a manufacturer trial percentage have different roles. No animal or in-vitro study is used here to prescribe treatment, and no sponsor-funded efficacy ranking is adopted.

Funding and source roles

The CDC final plan and gift policy establish public support and permitted gifts, not complete trial clearance. WHO’s actual routes include public and private support. Named Yellow Book contributor interests remain unclosed; neither source is treated as a financially cleared vaccine or antibiotic comparison.

Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.

Frequently asked questions

Are typhoid and ordinary Salmonella food poisoning the same?
No. Typhi/Paratyphi cause systemic enteric fever; other Salmonella commonly cause gastroenteritis. Clarify the organism and sample.

Can typhoid cause constipation?
Yes, constipation or diarrhoea may occur. Fever and significant illness still need assessment.

Does typhoid vaccination prevent paratyphoid?
Available typhoid vaccines are not licensed protection against paratyphoid. Maintain suitable food and water precautions.

Does a Widal test confirm typhoid?
CDC advises against relying on it because of false positives. Ask about appropriate cultures and the clinical assessment.

Can I return to food-handling work as soon as I feel well?
Obtain local clinical/public-health clearance. Feeling better does not establish that carriage has ended.

What if fever returns after treatment?
Seek prompt reassessment. Relapse, reinfection, ongoing infection or another cause may require investigation; do not reuse a leftover drug.

Sources and funding notes

Actual April/May2024 CDC bodies, August2025 symptom update, July13,2026 prevention page, full April23,2025 Yellow Book and October30,2019 vaccine statement were read. The named chapter author and underlying-study chains remain unclosed. The July2,2025 NHS condition source and January30,2026 azithromycin interactions were opened separately. WHO March30,2023 is dated context; its old vaccine count/duration claims are not presented as current2026 facts. WHO own funding/Geneva contact and CDC/NHS/NCCIH financial originals were checked separately. US empirical guidance is not a personal worldwide antibiotic prescription; no numerical mortality/cure rate, vaccine schedule, fluid amount or safe fever-waiting deadline is supplied.

• CDC: typhoid/paratyphoid overview, April2024 — Organisms and human-stool contamination/carriage context.
• CDC: symptoms, August2025 — Prompt fever/illness assessment; no safe waiting period.
• CDC: treatment, April2024 — Attributed prescriptions, food-handling and work clearance.
• CDC: prevention, July2026 — Food/water and typhoid vaccination; no paratyphoid license claim.
• CDC: clinical guidance, April2024 — Culture/Widal limits and dated US resistance-guided framework; no drug regimen.
• CDC: clinical overview, May2024 — Exposure and XDR context; no individual destination risk score.
• CDC: laboratory information, May2024 — US public-health sample route; not a patient direct-access service.
• CDC Yellow Book: enteric fever, April2025/2026 edition — Actual full chapter; nontyphoidal distinction, differential diagnosis and follow-up only.
• CDC: typhoid vaccine statement, October2019 — Attributed immune/pregnancy/antibiotic precautions; no schedule or numeric benefit.
• NHS: typhoid fever, July2025 — Emergency bleeding/pain, travel and reassessment warnings.
• NHS: azithromycin interactions, January2026 — Medicine review only if actually prescribed.
• NHS: sepsis, May2026 — Emergency deterioration warnings; no self-diagnosis threshold.
• WHO: original typhoid fact sheet, March2023 — Human-host/systemic disease and endemic-programme context; no numerical vaccine superiority.
• WHO: actual funding routes — Institution finance only; historical shares are not current2026 percentages.
• WHO: actual headquarters contact — Country/HQ trace only.
• NHS: dehydration, May2026 — Assessment/rehydration and urgent shock signs; no infant fluid prescription.
• NHS: acute kidney injury, March2026 — Acute illness, fluid and medicine review; no self-stop or drink-volume rule.
• NCCIH: probiotics safety, August2019 footer — Strain-specific evidence and vulnerable-patient safety, not independent pathogen-specific efficacy.
• NCCIH: supplement precautions, January2019 — Prescription/supplement interaction disclosure only.
• NCCIH: actual FY2025 congressional-justification index — Institution-level source finance only; no supplement benefit claim.
• CDC: original FY2026 operating plan — Actually opened four-page final operating plan; budget request not substituted.
• CDC: original gift administration policy, December2016 — Full24-page original opened; authority is not proof a company funded a disease page.
• CDC: actual May2024 headquarters contact — Agency country/HQ trace only.
• NHS: original October2022 content policy — Actual policy and date checked; underlying trials not cleared.

Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.